Getting relapsed and refractory patients
actionable information in record time
The MMRF Molecular Profiling Initiative
Running out of treatment options, and
Speed, of course, is of the essence.
time, can be a very real setback for
So we’re returning the genetic analysis
multiple myeloma patients who relapse
of the patient’s tumor in record time:
or become refractory to existing drugs.
10-14 days, so that physicians can
This is why an innovative new effort
rapidly identify trials or treatments
sponsored in part
critical to the MMRF Precision
depending on the results. And because
by the MMRF. As a
Medicine Model — called the MMRF
the MMRF is supporting the cost,
Molecular Profiling Initiative (MPI) —
volunteer for these
there is no financial burden on the
is so promising … and important. Our
patient whatsoever.
goal: determine if multiple myeloma
patients would benefit from available
drugs depending on molecular alterations
present in the tumor. Sequencing of
myeloma cells will be able to identify
How patients can
take advantage of the MPI.
As of now, patients can have this
“I’ve been in three
clinical trials all
trials, I am looking to help others
in any way, shape, or form.”
— Gary Rudman, multiple myeloma
patient and MMRF donor
analysis done at many MMRC sites
throughout the country, including
Benefitting the broader
Baylor, University of Michigan,
research community, too.
Washington University, Karmanos,
The MMRF Molecular Profiling
City of Hope, Ohio State University,
Initiative is also part of the MMRF’s
Why do we need
Hackensack, Princess Margaret
broader effort to “democratize” data
Clinical Grade sequencing?
Hospital, University of California at
that will accelerate research toward a
Clinical Grade is different than Research
San Francisco, Virginia Cancer Specialists
cure. The de-identified data (to protect
Grade sequencing because the results
and Mount Sinai. More MMRC sites are
a patient’s identity) will be gathered
can go directly to the doctor, who can
expected to open this profiling protocol
in this initiative to complement and
then share them with their patient.
over the next few months, with a total
augment existing datasets in the
If the data reveals an actionable
of 500 relapsed/refractory patients to
Multiple Myeloma Genomic Initiative
mutation, it can provide a relapsed/
be profiled over the next two years. The
(MMGI) and the MMRF CoMMpass
refractory patient essential guidance
Molecular Profiling Initiative is being
StudySM. De-identified data will be added
in identifying appropriate clinical trials
performed as part of a collaboration
to the publicly accessible researcher
or approved treatments that may
with the University of Michigan; the
platform — yet another example of
immediately benefit them.
clinical grade sequencing platform was
how the MMRF, in collaboration with
developed by the Michigan Oncology
research and academic centers, is
Sequencing Center and has been used
moving aggressively to harness the
to sequence other cancers.
incredible promise of patient data.
these alterations (also called “actionable
mutations”) and match them to specific
therapies.
NE W I N I T I AT I VE S
11